Cancer Drugs Fund | pharmaphorum

Skip to main content

Sunday 31 May 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Cancer Drugs Fund

News

Natural killer cells are a type of lymphocytes which destroy cancer cells and other altered cells releasing cytotoxic granules.

Government wasted £1.3 billion on Cancer Drugs Fund, says st...

The £1.3 billion of public expenditure on the old Cancer Drugs Fund (CDF) did not deliver value to patients or society, according to a new study.

News

NICE1

Janssen's Imbruvica recommended in CLL

J&J unit awaiting decisions in two more blood cancer uses.

UK & Europe

AAGill

AA Gill takes swipe at NICE in final column

NHS initially denied late writer immunotherapy.

News

Imbruvica

Janssen’s Imbruvica latest to gain NICE approval after price...

Leukaemia drug latest cancer treatment to gain NICE approval

News

NICE1

Price cut brings ‘breakthrough’ NICE approval of Perjeta

NICE says price cut made approval possible, despite continuing uncertainty about benefits

News

Natural killer cells are a type of lymphocytes which destroy cancer cells and other altered cells releasing cytotoxic granules.

NICE recommends Afinitor, Xalkori, as cancer drug review con...

NICE has recommended two cancer drugs, as it continues its review of treatments in the old Cancer Drugs Fund.

Load more results

Editor's Picks

GBL joins CVC in €10.7bn takeover bid for Recordati

After refusing to resign, CDER head Høeg is fired

As Ebola deaths climb, search begins for vaccine

NICE changes stance on Genmab's cervical cancer drug

Remepy's hybrid Parkinson's therapy poised for phase 3

Oncology

Interview at ASCO 26 with David Spetzler

ASCO26: AI supercharging gene-based cancer detection, with D...

Pharmaphorum caught up with Caris Life Science's David Spetzler to talk about how agentic AI is empowering whole genome sequencing in cancer detection

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company